MGF
A splice variant of IGF-1 produced in response to mechanical stress on muscles, promoting satellite cell activation and muscle repair.
What is MGF?
MGF (Mechano Growth Factor) is a splice variant of IGF-1 (specifically the Ec isoform in humans) that is produced locally in muscle tissue in response to mechanical loading (exercise). It activates muscle satellite (stem) cells, initiating muscle repair and growth. Synthetic MGF has a very short half-life of minutes.
What MGF Is Investigated For
MGF is used almost exclusively in bodybuilding circles for post-workout satellite cell activation and localized muscle repair, built on Geoffrey Goldspink's 1990s discovery that mechanical loading produces a distinct IGF-1 splice variant (IGF-1Ec) with a unique C-terminal E-domain that activates muscle stem cells. The strongest evidence is mechanistic and preclinical — MGF's role in load-gated satellite cell proliferation before differentiation is reasonably well-characterized in vitro and in rodent models. Human clinical evidence for synthetic MGF is essentially absent: no Phase 2 or 3 trials for any indication, no pharmacokinetic or dose-ranging data in humans, and the specific receptor mediating E-domain effects remains incompletely characterized. Practical use is further complicated by MGF's extreme instability in solution (activity lost within hours to a day) and the fact that PEG-MGF, which solves stability, changes the pharmacology away from the localized pulsatile mechanism that motivated the peptide in the first place. Independent replication of Goldspink's foundational work has been thinner than ideal, making this one of the more mechanistically speculative growth-factor peptides in common use.
History & Discovery
Mechano Growth Factor was characterized in the 1990s by Geoffrey Goldspink and colleagues at the Royal Free & University College London Medical School, who showed that mechanical loading of skeletal muscle produces an alternatively spliced IGF-1 transcript — IGF-1Ec in humans, IGF-1Eb in rodents — distinct from the systemic liver-derived IGF-1Ea isoform. Their central insight was that the local muscle response to loading and damage is not simply a spillover of hepatic IGF-1 but a distinct, mechanically gated splicing event producing a peptide with a unique C-terminal E-domain. Goldspink's group proposed that this E-domain activates satellite cells and expands the muscle stem-cell pool before the IGF-1 portion, once cleaved, drives downstream differentiation and hypertrophy. Synthetic MGF — typically the isolated E-domain sequence or the intact IGF-1Ec analogue — followed into research supply in the 2000s, and a PEGylated variant (PEG-MGF) was developed specifically to address MGF's intrinsic instability. Bodybuilding-market adoption arrived soon after, with the positioning that post-workout MGF injection would amplify the mechanically triggered satellite cell response. Published human data on synthetic MGF remains sparse; most evidence is in vitro or rodent, and the precise receptor mediating E-domain effects has been debated rather than definitively characterized. No therapeutic development program has advanced MGF toward regulatory approval.
How It Works
When you exercise hard, your muscles naturally produce MGF to activate stem cells that repair and grow muscle tissue. Synthetic MGF aims to amplify this natural repair signal.
MGF is produced by alternative splicing of the IGF-1 gene in response to mechanotransduction. The unique C-terminal E-domain peptide activates muscle satellite cells through a distinct receptor (not IGF-1R), promoting their proliferation without premature differentiation. This expands the satellite cell pool before IGF-1Ea (the systemic isoform) drives their differentiation into mature myofibers. MGF also has neuroprotective properties through similar stem cell activation in neural tissue.
Evidence Snapshot
Human Clinical Evidence
Very limited. Primarily studied in exercise physiology research.
Animal / Preclinical
Moderate. Satellite cell activation and muscle repair demonstrated in animal models.
Mechanistic Rationale
Moderate. MGF-specific receptor and signaling are still being fully characterized.
Research Gaps & Open Questions
What the current literature has not yet settled about MGF:
- 01No human clinical trials of synthetic MGF for any indication — the entire translation from Goldspink's splicing biology to injectable-peptide use rests on preclinical and in vitro data.
- 02Receptor identity and pharmacology — the specific receptor for the isolated E-domain remains incompletely characterized; whether synthetic E-domain peptides engage that receptor in humans with the kinetics implied by the mechanism is not firmly established.
- 03Stability and in-vivo bioavailability — native MGF's half-life is on the order of minutes, and the proportion of an injected dose that reaches and activates target tissue before degradation is not quantified in humans.
- 04Comparative effect of MGF versus PEG-MGF in humans — PEGylation extends half-life but may alter the mechanistic premise (mechanically localized, acutely timed response); head-to-head human data is absent.
- 05Independent replication — the MGF mechanistic framework is strongly associated with Goldspink's research program, and independent replication of key findings in other labs and species is thinner than would be ideal.
- 06Long-term local muscle tissue effects — repeated IM injection of a satellite-cell-activating peptide into the same muscle could plausibly affect fiber-type composition, fibroblast activity, or fibrotic change; no systematic human study exists.
Forms & Administration
IM injection into target muscle immediately after training. Typical research dose: 100-200mcg per site. Must be used within minutes of reconstitution due to instability. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Community protocols most commonly describe 100–200 mcg per injection site, sometimes up to 400 mcg when multiple muscle groups are targeted across a session. These figures are convention from online sources, not clinical evidence — no human dose-ranging study of synthetic MGF has been conducted.
Frequency
Post-workout intramuscular injection into the trained muscle is the standard described cadence, because the mechanistic rationale — amplifying the load-triggered satellite cell response — depends on proximity to mechanically damaged tissue. Injection is typically timed within minutes to an hour of training. Non-training days are usually skipped. PEG-MGF, by contrast, is dosed less frequently (2–3x weekly) and without the strict post-workout timing because of its extended half-life.
Timing Considerations
Time of day
Ties to training schedule rather than clock time.
Relative to meals
Often paired with a post-workout protein-and-carbohydrate meal.
Relative to exercise
Injected post-workout into the trained muscle group, typically within 30–60 minutes of training. MGF is mechano-growth factor — the biological rationale is that muscle damage from training opens the window where its myogenic signaling is most active, so injection timing tracks that window tightly.
Cycle Length
4–6 weeks on, 4 weeks off is the most commonly described cycling pattern. Rationale offered in the community is satellite-cell response saturation and general caution about chronic supraphysiologic growth-factor exposure. These are not derived from human trial data.
Protocol Notes
Synthetic MGF is notoriously unstable in solution. Reconstituted peptide loses activity within hours to a day at room temperature, and community practice reflects this: reconstitute immediately before injection, or store reconstituted product cold and use within a short window. PEG-MGF addresses this with a polyethylene glycol modification that meaningfully extends both shelf life and circulating half-life, at the cost of the strict post-workout localization rationale. Intramuscular injection into the belly of the trained muscle using a small-gauge insulin syringe is the convention. As with DES, repeated injection into the same site risks local fibrosis and infection, and site rotation across training sessions is standard practice. All of the above describes community convention, not validated human protocols. Most published MGF evidence is preclinical. Synthesis quality is a practical concern — the correct IGF-1Ec E-domain sequence versus truncated, misfolded, or mis-sequenced product is not reliably verified in the research-chemical market.
These numbers describe community practice, not a prescription. Synthetic MGF is not FDA-approved for any indication. Most evidence is preclinical. Any actual use should be under the direct supervision of a qualified healthcare provider.
Timeline of Effects
Onset
Users commonly describe enhanced post-workout fullness and perceived recovery at the injected muscle within the first 1–2 training sessions. These reports are anecdotal. Published preclinical satellite cell proliferation kinetics operate over days, not hours, so acute subjective effects may not map cleanly onto the proposed mechanism.
Peak Effect
Reported hypertrophy and strength effects, where described, are most often in the 3–6 week window of a typical cycle, overlapping with the normal adaptation timeframe of resistance training. No human trial has isolated the MGF-specific contribution from training alone.
After Discontinuation
Unmodified MGF clears within hours after the last dose; PEG-MGF clears over days. Training-driven adaptations persist to the degree that training, nutrition, and recovery persist. The satellite-cell pool expansion proposed by Goldspink would, if real at pharmacologic doses, presumably leave some durable substrate for subsequent hypertrophy, but this has not been demonstrated in humans.
Common Questions
Who MGF Is NOT For
- •Active or recent-history cancer, particularly any muscle-origin or growth-factor-sensitive malignancy — MGF's satellite-cell activation and IGF-1R signaling raise theoretical tumor-promotion concerns that are not quantified in humans.
- •Pregnancy and breastfeeding — no safety data; growth factor signaling in developmental contexts is not a place to extrapolate.
- •Pediatric use (under 18) — no appropriate indication; skeletal muscle development and growth-plate biology involve the endogenous IGF-1 system already.
- •Known hypersensitivity to peptide therapeutics, excipients used in reconstitution, or PEG (for PEG-MGF specifically — PEG hypersensitivity is documented).
- •Active infection or significant scar tissue at the planned injection site.
- •Active acromegaly or untreated pituitary disorder — adding exogenous growth factor signaling is contraindicated.
Drug & Supplement Interactions
Clinical interaction data for synthetic MGF is absent; what follows is mechanistic extrapolation. Concurrent use with growth hormone, GH secretagogues (sermorelin, CJC-1295, ipamorelin, tesamorelin), MK-677, IGF-1 LR3, or IGF-1 DES compounds IGF-1 axis activation and may meaningfully raise systemic IGF-1 tone beyond what any single agent produces. The cardiovascular, glycemic, and cancer-risk implications of combined use are not characterized. Corticosteroids can blunt satellite cell response and may antagonize the proposed MGF mechanism. NSAIDs have been shown in some studies to attenuate post-exercise satellite cell activation; whether this meaningfully affects MGF response is unknown but plausible. Patients on IGF-1R-directed oncology therapies should not use MGF. Anabolic-androgenic steroids do not directly interact with the E-domain pathway but share cardiovascular and cancer-risk considerations. PEG-MGF specifically carries PEG-related interaction concerns — documented PEG hypersensitivity cross-reactivity with other PEGylated therapeutics (certain monoclonals, some vaccines) is worth disclosing to prescribing clinicians.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • Very limited human data
- • Extremely short half-life limits practical use
- • Must be injected immediately post-workout for best effect
What We Don't Know
Human safety profile is essentially unknown. Theoretical concerns about uncontrolled satellite cell activation.
Legal Status
United States
Synthetic MGF is not FDA-approved for any medical indication. It is sold through research-chemical channels labeled 'not for human use'; distribution for human consumption is unauthorized under the FD&C Act. It is not a scheduled controlled substance.
International
Not authorized as a medicine in the EU, UK, Canada, or Australia. Australian TGA treats it as a Schedule 4 prescription-only substance. European and other developed-market regulatory posture mirrors the US in treating it as an unapproved investigational agent.
Sports & Competition
Prohibited at all times under WADA as a growth factor. Although WADA assays have historically been best-developed for native IGF-1 and hGH, mass-spectrometric methods for detecting MGF specifically have been reported in the doping-control literature, and athletes subject to WADA, USADA, UKAD, or equivalent frameworks should consider MGF and PEG-MGF categorically prohibited in and out of competition.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
MGF is the 'missing signal' that unlocks muscle growth beyond what training alone can produce.
Reality
MGF is one of many signals in the load-response cascade, not a master switch. Most published evidence is preclinical. Human synthetic-MGF trials demonstrating hypertrophy beyond what training alone produces are not available. The mechanism is interesting; the clinical demonstration is not there.
Myth
MGF is safer than LR3 because it is more 'natural' and only acts locally.
Reality
The endogenous IGF-1Ec splice variant occurs at specific local concentrations during mechanically gated muscle repair. Injecting 100–200 mcg of synthetic E-domain or IGF-1Ec into muscle is not physiologically equivalent. Safety framing based on endogenous occurrence is not well supported.
Myth
PEG-MGF is equivalent to MGF with longer duration — you can just use it less often.
Reality
PEG-MGF's extended half-life changes the pharmacologic regime from a pulse tied to acute mechanical load to a more sustained systemic exposure. Whether the satellite-cell-activating mechanism holds in that regime is debatable rather than demonstrated. Convenience does not equal equivalence.
Myth
Synthetic MGF solves the instability problem that limits native MGF.
Reality
Unmodified synthetic MGF is still highly unstable in solution. The instability problem is intrinsic to the peptide, not to its source. PEG-MGF addresses stability at the cost of changing the pharmacologic profile. The research-chemical market solves neither problem with QA-grade manufacturing.
Published Research
32 studiesEfficacy of mangiferin, kaempferol, and diosgenin on models of depression: A systematic review and network meta-analysis of rodent studies
The role of mechano growth factor in chondrocytes and cartilage defects: a concise review
The Roles of IGF-1 and MGF on Nerve Regeneration under Hypoxia- Ischemia, Inflammation, Oxidative Stress, and Physical Trauma
Resistance training variable manipulations are less relevant than intrinsic biology in affecting muscle fiber hypertrophy
Intraoperative graft flow profiles in coronary artery bypass surgery: A meta-analysis
The effects of a multigrowth factor-containing cream on recovery after laser treatment: a double-blinded, randomized, split-face controlled study
Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls
Biological activity of the e domain of the IGF-1Ec as addressed by synthetic peptides
Ageing is associated with diminished muscle re-growth and myogenic precursor cell expansion early after immobility-induced atrophy in human skeletal muscle
Compliance with school F-milk and non-F milk intake in 3 to 4 and 6 to 7-year-old children
[Expression of mechano-growth factor and its roles in tissue repairs and regeneration]
Overload training inhibits phagocytosis and ROS generation of peritoneal macrophages: role of IGF-1 and MGF
The effect of strength training volume on satellite cells, myogenic regulatory factors, and growth factors
Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages
Clinical value of intra-operative transit-time flow measurement for coronary artery bypass grafting: a prospective angiography-controlled study
Effects of preexercise feeding on markers of satellite cell activation
Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration
Coordinated increase in skeletal muscle fiber area and expression of IGF-I with resistance exercise in elderly post-operative patients
Effects of different intensities of resistance exercise on regulators of myogenesis
Muscle expressions of MGF, IGF-IEa, and myostatin in intact and hypophysectomized rats: effects of rhGH and testosterone alone or combined
Serum IGF-I levels and IGF-I gene splicing in muscle of healthy young males receiving rhGH
Androgen receptors and testosterone in men--effects of protein ingestion, resistance exercise and fiber type
Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction
Effects of rehabilitative exercise on peripheral muscle TNFalpha, IL-6, IGF-I and MyoD expression in patients with COPD
Quantitative histology and MGF gene expression in rats following SSC exercise in vivo
Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting
Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting
The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men
Fluoride uptake in situ after the use of dental floss with fluoride
Combined fluoride therapies. A 6-year double-blind school-based preventive dentistry study in Inverness, Scotland
The emerging neuropoietic cytokine family: first CDF/LIF, CNTF and IL-6; next ONC, MGF, GCSF?
Analyzing mast cell development and function using mice carrying mutations at W/c-kit or Sl/MGF (SCF) loci
Quick Facts
- Class
- Growth Factor Splice Variant
- Tier
- D
- Evidence
- Emerging
- Safety
- Limited Data
- Updated
- Mar 2026
- Citations
- 32PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.